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Targeted therapies in the management
of metastatic bladder cancer
Matteo Fassan
Edouard J Trabulsi
Leonard G Gomella
Raffaele Baffa
Department of Urology, Kimmel
Cancer Center, Thomas Jefferson
University, Philadelphia, PA, USA

Abstract: The management of metastatic urothelial carcinoma (UC) of the bladder is a common
and complex clinical challenge. Despite the fact that UC is one of the most frequent tumors
in the population, long term survival for metastatic disease remains low, and chemotherapy
is curative for only a small minority of patients. UC is genetically heterogeneous, and it is
surrounded by a complex tissue microenvironment. The problems of clinical practice in the
ﬁeld of metastatic bladder cancer have begun to stimulate translational research. Advances in
the understanding of the molecular biology of urothelial cancer continue to contribute to the
identiﬁcation of molecular pathways upon which new therapeutic approaches can be targeted.
New agents and strategies have recently been developed which can direct the most appropriate choice of treatment for advanced disease. A review of literature published on the targeted
therapy for metastatic bladder cancer is presented, focusing on the molecular pathways shut
down by the new therapeutic agents.
Keywords: bladder cancer, metastasis, gene targeting, gene therapy, molecular biology
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The design and development of agents that act on speciﬁc molecular and cellular targets
are considered as a rational approach to control cancer. This strategy for control of
cancer is based on the presumption that because cancer develops through a multi-step
process, each step may be a prospective target for reversing or suppressing the process.
There are a number of limitations on drug targeting technology, but, at present, the
more difﬁcult limitations are imposed by tumors themselves and by the host’s response
to a tumor. Moreover, successes in vitro are disputable without corresponding data in
the more composite organism level.
Bladder cancer is one of the most common cancers, being the 4th most common
malignancy in men and the 13th most common malignant cancer in women in the
United States (Jemal et al 2007). In 2007, it is estimated that 67,160 new cases of
bladder cancer will be diagnosed, and 13,750 deaths will be attributed to this disease
(Jemal et al 2007). The incidence is higher in males (with a ratio of 3:1) and in the
elderly (Jemal et al 2007). Urothelial carcinoma (UC) (previously designated as transitional carcinoma or TCC) accounts for approximately 95% of bladder malignancies
(Baffa et al 2006).
Despite undergoing surgery with curative intent, a large proportion of patients with
UC will develop metastatic disease while others will have metastases at the time of
initial presentation (Calabro and Sternberg 2006). Accurate clinical staging of bladder cancer remains difﬁcult and inaccurate, with pathologic upstaging after radical
cystectomy commonly demonstrated for clinically localized tumors (Ficarra et al
2005). Recent studies have demonstrated that combination therapy with neoadjuvant
chemotherapy followed by radical surgery for muscle-invasive diseases offers a small
but deﬁnite survival advantage (Grossman et al 2003; Vale 2005). Once metastatic,
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however, the relative 5-years survival rate is 6%, whereas
the overall 5-years survival for all stages is 82% (Mitra et al
2006). For patients with muscle-invasive disease, the most
common pattern of metastasis is to regional lymph nodes,
but distant spread to lungs, liver, skin and bone is also typical (Raghavan et al 1990). Metastases to abdominal viscera,
brain, and meninges are seen less frequently.
Sites of metastatic involvement correlate with response
rate and survival and are important predictors of treatment
outcome (Parimoo and Raghavan 2000). Patients with lymph
node, lung, and soft-tissue metastases have better survival
than those with metastases to bone and liver (Geller et al
1991; Loehrer et al 1992). Biopsies of distant metastatic sites
are often consistent histologically with UC pattern. However,
a signiﬁcant disparity within these metastatic lesions with
respect to growth parameters, ploidy, karyotype, oncogene
expression, tumor markers, grade, and histologic features has
been demonstrated (Raghavan et al 1990; Geller et al 1991;
Loehrer et al 1992).
Patients with metastatic UC are usually treated with systemic chemotherapy (Sternberg et al 1989; Geller et al 1991;
Pagano et al 1991; Calabro and Sternberg 2006). For more
than two decades, the standard treatment has been combination therapy with methotrexate, vinblastine, adriamycin and
cisplatin (MVAC). This regimen is consistently reported to
produce a median survival in the range of 13–15 months
(Sternberg et al 1989; Calabro and Sternberg 2006). MVAC
has signiﬁcant toxicity, however, primarily neutropenia,
neutropenic fever and severe mucositis, which limits its
use in the predominantly older bladder cancer population.
Combination therapy with gemcitabine and cisplatin (GC)
has shown similar efﬁcacy as MVAC, with less toxicity
and a much lower toxic death rate (1% vs 3% for MVAC),
leading to widespread substitution of GC for MVAC in
clinical practice (von der Maase et al 2000). In the search
for regimens more active than MVAC, regimens based on
gemcitabine, ifosfamide, and/or paclitaxel have attracted
considerable interest (Roth et al 1994; Bajorin et al 1998;
Redman et al 1998; Vaughn et al 1998), but until now no
substantial improvement in survival has been observed. Most
of these treatments are based on the pathologic staging of
tumors and do not take molecular proﬁles into consideration.
These facts highlight the limited effectiveness of the current
therapeutic regimens and that novel treatment strategies are
urgently required. Novel targeted therapies hold promise to
improve the current results of metastatic bladder cancer treatment. Several trials are ongoing evaluating these new agents
alone or in combination with chemotherapy. The integration
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of these newer biologic agents should be a primary direction
of research with the objective to interfere with multiple
aspects of bladder cancer progression.

Molecular events in metastatic
bladder cancer
The identification of mutated genes and gene products
which are aberrantly expressed in invasive and metastatic
bladder tumors permits the design of molecularly targeted
therapies. There have been recent major developments in our
understanding of the molecular phenotype of bladder cancers
(Table 1) (Dimopoulos and Moulopoulos 1998; Knowles
2001; Cote and Datar 2003; Baffa et al 2006; Abraham et al
2007). Over the last two decades, scientists have demonstrated that two distinct molecular pathways are involved
in the genesis of UC based on histopathology and clinical
behavior (Figure 1) (Wu 2005; Baffa et al 2006): superﬁcial
papillary and invasive non-papillary bladder tumors.
Papillary carcinoma, which account for more than 80%
of bladder tumors, has a tendency to recur locally (approximately 70%), but rarely invades and metastasizes. On the
other hand, most invasive bladder tumors have no known
papillary precursor, are solid invasive lesions, are commonly
associated with carcinoma in situ (CIS) and have a much
less favorable prognosis. Genetic analyses have shown that
CIS exhibits a spectrum of genetic alterations (such as TP53
mutation and loss of heterozygosity -LOH- at 3p, 8p, 13q,
and 17p) similar to that seen in invasive UC and very distinct
from that seen in low grade papillary UC, where only LOH
at chromosome 9 is common (Wu 2005).
In invasive and metastatic bladder cancers, among the
different oncogenes and tumor suppressor genes (TSG)
which have been studied (Table 1), particular interest has
been focused on defects in pathways controlling the G1/S
cell cycle checkpoint (involving the tumor suppressor genes
TP53 and RB1), angiogenesis, DNA methylation, multidrugs
resistant genes and on activation of the Ras-MAPK signal
transduction pathway, in which associations between molecular abnormalities and tumor prognosis have been identiﬁed
(Knowles 2001).

Cell cycle regulators
A prerequisite for normal cell proliferation is an orderly
progression through the cell cycle, which is predominately
controlled by protein complexes that are composed of cyclins
and cyclin-dependent kinases (CDK). These complexes control progression through the cell cycle by phosphorylating
key proteins that are involved in cell cycle transition points.
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LOH, point mutation
LOH, point mutation
Unknown
Unknown

RB1 (13q14)

TP53 (17q14)

NF-1 (17q11)
BC10 (20q11.1-q12)
Activating mutation
Amplification
Amplification
Activating mutation
Amplification, chromosomal rearrangements
Amplification
Amplification
Amplification

FGFR3 (4p16)
EGFR (7q11.2-q12)

C-MYC (8q24)
H-RAS (11p15.5)
CCND1 (11q13)
MDM2 (12q13-14)

ERBB-2 (17q21.1)

STK15/BTAK (20q13)

Oncogenes

LOH, methylation
Down-regulation, point mutation
LOH, point mutation
LOH, methilation, point mutation
LOH, point mutation
LOH, point mutation
LOH, point mutation
Point mutation

Alteration

FHIT (3p14.2)
CDKN1A (6p21)
FEZ1/LZTS1 (8p22)
CDKN2A (9p21)
PTCH (9q22)
TSC1 (9q34)
PTEN (10q23)
CDKN1B (12q12)

Tumor suppressor genes

Gene
(chromosomal location)

Table 1 Principal genes altered in urothelial bladder carcinoma

– (Cappellen et al 1999; Sibley et al 2001)
Progression (Chow et al 1997; Lipponen and Eskelinen 1994; Mellon et al 1995; Messing 1990; Neal et al 1990;
Ravery et al 1997; Sriplakich et al 1999;Vollmer et al 1998)
Progression (Christoph et al 1999; Mahdy et al 2001; Sardi et al 1998)
Recurrence (Fitzgerald et al 1995; Fontana et al 1996)
Progression (Proctor et al 1991; Shin et al 1997; Watters et al 2002)
Progression, survival (Habuchi et al 1994; Lianes et al 1994; Schmitz-Drager et al 1997; Shiina et al 1996; Shiina et al
1999; Uchida et al 2002)
Metastatic disease, survival (Chow et al 2001; Coombs et al 1991; Gandour-Edwards et al 2002; Jimenez et al 2001;
Mellon et al 1996; Moriyama et al 1991; Underwood et al 1995)
Metastatic disease, survival (Sen et al 2002)

Survival, muscle invasion (Baffa et al 2000; Skopelitou et al 2001;Vecchione et al 2004)
Recurrence, survival, response to chemotherapy (Shariat et al 2004; Stein, Ginsberg et al 1998)
Progression (Vecchione et al 2002)
Recurrence (Orlow et al 1999)
– (McGarvey et al 1998)
– (Hornigold et al 1999)
– (Aveyard et al 1999; Cairns et al 1998; Wang et al 2000)
Recurrence, progression, metastatic disease, survival (Franke et al 2000; Kamai et al 2001; Korkolopoulou et al 2000;
Lacoste-Collin et al 2002; Sgambato et al 1999)
Progression, muscle invasion, survival (Cairns et al 1991; Cordon-Cardo et al 1992; Grossman et al 1998; Logothetis
et al 1992; Xu et al 1993)
Progression, muscle invasion, survival, response to chemotherapy (Cote et al 1997; Esrig et al 1993; Lipponen 1993;
Lu et al 2002; Pfister et al 1998; Pfister et al 1999b; Sarkis et al 1993, 1995; Sidransky et al 1991; Soini et al 1993)
– (Aaltonen et al 1999; Uchida et al 1995)
Muscle invasion (Gromova et al 2002)

Clinical association (References)
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Figure 1 Proposed model for urothelial tumorigenesis and progression. Papillary tumors and carcinoma in situ (CIS) have unique molecular profiles and arise from two
distinct pathways.

The fundamental and best studied genes involved in cell
cycle regulation are the tumor suppressor genes RB1, TP53,
CDKN2A (P16/INK4A-ARF) and CDKN1A (P21WAF1/
Cip1) and the oncogene MDM2.
The p53 protein is a central molecule in several important
cellular programs related to cancer development, progression and response to therapy, as apoptosis and DNA repair
(Cote et al 1997). It inhibits cell cycle progression at G1-S
transition and mediates its control through the transcriptional
activation of CDKN1A. TP53 mutations are the most common
genetic defect in human tumors (Hollstein et al 1991) and
most studies on TP53 have used immunohistochemical detection of the p53 protein as a surrogate for gene inactivation by
mutation. Mutant p53 has an increased half life and can be
easily detected, whereas normal physiological concentrations
of the wild-type protein are undetectable. The mutations are
generally missense point mutations, which result in altered
proteins that are resistant to normal regulatory degradation
by the ubiquitin pathway (Dowell 1995). In bladder cancer,
mutation of p53 is a feature of more advanced, poorly differentiated tumors and appears to be associated with a high
risk of metastatic recurrence and a poor prognosis (Esrig et al
1993; Lipponen 1993; Sarkis et al 1993, 1995; Soini et al
1993; Esrig et al 1994; Pﬁster, Flaman et al 1999; Pﬁster,
Moore et al 1999). TP53 has been evaluated in bladder cancer in order to predict and to be correlated with an increased
chemosensitivity (McKnight et al 2005; Stein, Grossfeld
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et al 1998). Adjuvant chemotherapy was associated with a
decreased risk of recurrence and improvement in survival
when given to patients with TP53-altered tumors (Cote et al
1997). In a transfected bladder cell line, the re-expression
of a wild-type p53 protein suppressed the cytotoxic effects
of paclitaxel and gemcitabine (Kielb et al 2001). Paclitaxel
was shown to require functionally mutated TP53 to induce
cell death, indicating that it may be more effective against
UC with TP53 mutations, while gemcitabine was effective
regardless of p53 protein function. Induction of TP53 gene
expression has been shown to be facilitated by prior exposure to cytotoxic agents such as cisplatin and mitomycin C
(Parimoo and Raghavan 2000). This altered expression of
TP53 may correlate with increased resistance to combination chemotherapy protocols (ie, MVAC) (Cote et al 1997;
Sarkis et al 1995) and may be associated with previous intravesicular treatment (Bajorin et al 1998). All these ﬁndings
may provide a rationale for selecting chemotherapy on the
basis of the TP53 status.
However, not all bladder tumors with TP53 alterations
progress or recur (Esrig et al 1993; Esuvaranathan et al 2007).
As previously described, the action of wild type TP53 on cell
cycle regulation is mediated, in part, through up-regulation of
CDKN1A (P21/WAF1). p21 protein, a CDK inhibitor, binds
and inhibits cdk2, a protein that is necessary for transition
into the next phase of the cell cycle. Alterations of TP53
result in loss of p21 expression, which leads to unregulated
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cell growth. However, it has been shown that p21 expression
can also be regulated through p53-independent pathways
which may maintain p21 expression despite the presence of
altered p53 (Kinoshita et al 1997). Thus, from a theoretical
point of view, p21 protein detection should provide additional
information to p53 positivity alone. In bladder cancer, the
loss of p21 expression can be a signiﬁcant and independent
predictor of UC progression, whereas the maintenance of
p21 expression appears to abrogate the deleterious effects
of TP53 alterations (Stein, Ginsberg et al 1998). In multivariate analysis, p21 labeling was an independent predictor
of tumor recurrence and of survival (Stein, Grossfeld et al
1998). Patients with TP53-altered/p21-negative tumors
demonstrated a higher rate of recurrence and worse survival
compared with those with TP53-altered/p21-positive tumors
(Migaldi et al 2000; Stein, Ginsberg et al 1998).
MDM2 is another gene correlated with TP53 expression.
In normal cells, MDM2 regulates TP53 function by marking
p53 protein for degradation via ubiquitin conjugation and
inactivating p53 by binding to its transactivation domain
(Oliner et al 1992; Wu et al 1993). Increased p53 levels
transactivate the MDM2 promoter causing its upregulation.
Ampliﬁcation of MDM2 results in the escape from TP53regulated growth control. Nevertheless, the role of MDM2
in regulating p53 protein levels in UC remains unclear.
It is generally agreed that Mdm2 over-expression itself
provides no independent prognostic information over
clinico-pathological parameters (Schmitz-Drager et al
1997; Shiina et al 1999; Uchida et al 2002). However, the
combination of MDM2 and TP53 status could determine a
higher prognostic power on progression (Schmitz-Drager
et al 1997; Shiina et al 1999) and survival (Shiina et al 1999)
in bladder cancer patients.
The RB1 gene was the ﬁrst tumor suppressor gene identiﬁed (Friend et al 1986). In its physiologic active form the
nuclear phosphoprotein Rb1 encoded protein inhibits cell
cycle progression at the G1 to S checkpoint by binding to a
number of cellular proteins including the transcription factor
E2F (Chellappan et al 1991). The inactivation of RB1 has
been described as an important step in carcinogenesis and
progression of various tumors (Bagchi et al 1991; Goodrich
2006). The comparison of immunohistochemical Rb1 expression and molecular analysis in primary UCs showed that
RB1 alterations (observed in the 19%–29.4% of the tumors)
are more frequently seen in muscle-invasive and high-grade
tumors (Cordon-Cardo et al 1992; Cordon-Cardo et al 1997;
Xu et al 1993), and that in patients with muscle-invasive
bladder cancer the 5-year survival was signiﬁcantly decreased
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in cases with altered Rb1 protein (Cordon-Cardo et al 1992;
Logothetis et al 1992; Gallucci et al 2005).
Important in the regulation of the cell cycle is also
the CDKN2A gene (also known as P16, INK4A, MTS1,
CDKN2A), which is a well-characterized CDK inhibitor
(Lo et al 1996). This protein functions upstream of Rb1
to block cyclin-D directed phosphorylation of Rb1, thus
inducing G1 arrest. CDKN2A mutations and homozygous
deletions have been detected in the 3.1% and 14.1% of
bladder cancers analyzed, respectively (Orlow et al 1999).
Furthermore, CDKN2A is thought to be susceptible to
transcriptional silencing by promoter methylation, which
affects from 14.9% to 26.5% of the tumors tested (Orlow
et al 1999; Chan et al 2002). Inactivation of CDKN2A by
any of the mechanisms will lead to affect both p16 and
p19ARF proteins, and subsequently disrupting the Rb1 and
p53 pathways (Orlow et al 1999).
The interaction of p53 and p21 proteins in cell cycle
regulation, and the data looking at the cooperative effects
of p53 and Rb1 (Cordon-Cardo et al 1997), provide good
examples of the increasing evidence that mutation in a single
TSG is unlikely to be the only factor resulting in carcinogenesis. Several studies have conducted multivariate analyses
using various combinations of cell cycle regulators markers (TP53, CDKN1A, RB1, CDKN2A, MDM2) to generate
prognostic panels (Lu et al 2002; Shariat et al 2003; Shariat
et al 2004). Lu et al (2002) and Shariat et al (2003) found
that the 12.1% of the 140 tumor analyzed, had an altered p53
pathway, deﬁned by the detection of mutant TP53 and/or p53
nuclear overexpression, loss of p21 nuclear expression, and
Mdm2 nuclear overexpression. Moreover, they exhibited
the worst clinical outcome in the observation period. Shariat
et al (Shariat et al 2004), found that the 83% of 80 bladder
cancers had at least one marker altered (p53, p21, and pRB
or p16), and 21 patients (26%) had all three altered. These
studies demonstrated a biological and pathological relationship between these markers spanning multiple molecular
pathways and progression, suggesting their important role
in bladder carcinogenesis and their rational target for the
design of molecularly targeted therapies.

Tumor angiogenesis
Angiogenesis is not only important in maintaining the supply
of oxygen and nutrients to the proliferating tumor cells and
to the metastatization of the primary tumor, but also for the
survival and spreading of secondary localizations. The most
important factor affecting this process is the pro-angiogenic
vascular endothelial growth factor (VEGF). High serum
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VEGF levels and VEGF IHC expression have been associated
with high UC stage and grade, vascular invasion, CIS, metastases and poor disease free survival (Bernardini et al 2001; Zu
et al 2006). Moreover, VEGF levels affect the production of
interleukin-8 (IL-8) and matrix metalloproteinases (MMPs)
(Nutt et al 1998), which enhances angiogenesis of the tumor,
and migration and invasion of bladder cancer cells. Increased
expression of MMP-9, IL-8 and VEGF has been proven to
be correlate with stage and outcome of advanced bladder
tumors (Black and Dinney 2007).

DNA methylation
The promoter methylation has been demonstrated to be
a frequent mechanism of inhibition for important genes
including those that inﬂuence the cell cycle and signal transduction in cancer (Chan et al 2002). In UC, the role of this
epigenetic event in the silencing of TSGs is still under study.
The promoter region of TP53 gene is almost never methylated in muscle-invasive UC (Kunze et al 2006), whereas, as
mentioned above, CDKN2A is susceptible to transcriptional
silencing by promoter methylation (Orlow et al 1999; Chan
et al 2002). Recently, additional ﬁndings are conﬁrming
the importance of this mechanism in the process of bladder
metastatization (Nixdorf et al 2004). Further studies should
elucidate the signiﬁcance of hyper-methylation and the role
of demethylating agents in the treatment of locally advanced
and metastatic UCs (Cote and Datar 2003).

Multidrug resistant genes
The tumor resistance to chemotherapy is the major problem
affecting the management of metastatic and aggressive bladder cancers. Over-expression of the MDR1 gene leads to drug
resistance via up-regulation of a membrane-bound 190 kDa
phosphoglycoprotein, that serves as an energy-dependent
drug ﬂux pump and eliminates toxic metabolites out of the
cells (Hasegawa et al 1995). The expression of this protein
correlated in various tumors with low local drug accumulation and increased drug resistance (Endicott and Ling 1989),
which has also been observed in bladder cancer (Clifford et al
1994; Naito et al 1992; Petrylak et al 1994). Petrylak et al
(1994), observed a positive p-glycoprotein immunostaining
in 6 of 46 untreated primary lesions (13%), while 6 of 16
(38%) post-therapy primary tumors were immunoreactive.
None of the untreated metastases (0 of 17) were positive;
however, 6 of 11 (55%) post-therapy specimens showed
varied percentages of positivity. Of interest, the highest
percentage, 50%–70% of tumor cells stained, was observed
in metastatic lesions from patients who had received 6 or
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more chemotherapy cycles. These characteristics suggest
that targeting of MDR1 expression may improve the response
of advanced and metastatic bladder tumors to systemic
chemotherapy.

Growth factor receptors
In invasive and metastatic UC two receptor tyrosine kinases,
the epidermal growth factor receptor (EGFR) and ERBB-2
(also called HER-2 or NEU), are over-expressed (35%–86%
for EGFR, and 41%–52% for ERBB-2) and associated with
poor outcome (Lipponen and Eskelinen 1994; Ravery et al
1997; Kruger et al 2002; Hussain et al 2007)
Preclinical and clinical data strongly support the
involvement of the EGFR in the growth and progression of
human cancers (Nicholson et al 2001; Mendelsohn 2002;
Dei Tos 2007) as well as demonstrate a high correlation in
cancer patients between receptor/ligand expression and poor
prognosis (Nicholson et al 2001). EGFR is a transmembrane
glycoprotein that is activated by the binding of epidermal
growth factor (EGF) and of transforming growth factor (TGF)
to its external domain. In normal cells, binding of EGF causes
activation of the EGFR, leading to receptor dimerization and
autophosphorylation. The activated receptor then recruits
proteins that convert Ras to its activated state, which can then
transduce a mitogenic signal through the Ras-MAPK pathway
by activating the MAPK/ERK complex. This activation sets
off several cell regulation processes such as proliferation,
migration and adhesion (Messing 1990; Messing 1992;
Roberts and Der 2007). Although the mechanism by
which EGFR regulates tumor biology in bladder cancer is
not clearly deﬁned, it has been demonstrated that EGFR
signaling regulates cellular proliferation, differentiation,
survival, invasion; and it is implicated in the induction of
tumor induced angiogenesis and metastasis (Mendelsohn
and Dinney 2001; Nicholson et al 2001).
Immunohistochemical studies have demonstrated that
EGFR is over-expressed in human UC compared to the normal urothelium (Neal and Mellon 1992; Rotterud et al 2007).
Moreover, it has been observed that normally the urothelial
cells which over-express EGFR are found primarily in the
basal layer of the urothelium (Messing 1990; Messing 1992;
Rotterud et al 2007), whereas, in malignant and dysplastic
urothelium, EGFR is expressed in all cell layers (Baffa et al
2006). Most importantly, it has also been observed that the
level of EGFR expression directly correlates with tumor
grade, stage, and survival (Neal et al 1990; Messing 1992;
Lipponen and Eskelinen 1994; Mellon et al 1995; Chow et al
1997; Popov et al 2004). Patients with muscle-invasive UC
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which over-express EGFR have only a 20% probability of
long term cancer-speciﬁc survival, which is signiﬁcantly
worse than the survival of those whose tumors did not express
EGFR (Nguyen et al 1994). In metastatic bladder cancer,
the majority of metastases from patients over-expresses the
EGFR, and this expression is not down-regulated by chemotherapy or radiation (Nguyen et al 1994).
In normal and malignant cells, the preferred partner for
the EGFR molecule is erbB-2, a member of the ERBB gene
family, and encoded by the ERBB-2/HER-2/NEU gene. This
heterodimeric formation acts as the most efﬁcient receptor
for EGF. As observed in breast, gastric and ovarian cancers, the erbB-2 protein was found to be over-expressed
frequently in urinary bladder carcinoma (Messing 1992;
Sato et al 1992; Roberts and Der 2007) and it has also
been found associated with increasing tumor grade, poor
survival and incidence of metastatic disease (Moriyama
et al 1991; Sato et al 1992; Gandour-Edwards et al 2002).
The prognostic power of its over-expression increases when
combined with other erbB receptors (especially EGFR
and erbB-3) (Chow et al 2001). Of interest, in one study

(Jimenez et al 2001) almost 70% of erbB-2 negative primary
muscle-invasive tumors had erbB-2 positive corresponding
distant metastasis.

From the bench to the bedside
Advances in the understanding of the molecular biology of
UC continue to contribute to the identiﬁcation of molecular
pathways upon which new therapeutic approaches can be
designed. The goal of targeted therapy is to optimize the
therapeutic ratio of an anti-neoplastic drug by maximizing
its effect on tumor cells, and at the same time minimizing toxicity for normal cells. Various approaches have
been developed to speciﬁcally targeting the phenotype of
tumors. Such therapies involve the use of antibodies or
small molecule enzyme inhibitors which interact with speciﬁcally target molecules differentially expressed between
tumor and normal cells. In Table 2 the wide range of novel
therapeutic agents (viral vector carrying wild-type genes,
small molecule inhibitors and monoclonal antibodies) are
summarized. Many of these agents are being introduced in
clinical trials.

Table 2 Innovative targeted agents for metastatic bladder cancer treatment
Target

Agent

Mechanism of action

p53 mutated
p53 mutated
p53 mutated
p53 wild-type and mutated

AdCMV-TP53
rVV-TK-53
ONYX-015
CP-31398

p53 mutated
Rb-positive and negative cells
Cyclin-dependent kinases
Cyclin-dependent kinases
EGFR
EGFR
EGFR
erbB2

PRIMA-1
Ad-Rb94
Flavopiridol
UCN-01
Gefitinib
Erlotinib
Cetuximab
Trastuzumab

Receptor tyrosine kinase

Sorafenib

VEGF
VEGF
VEGF
VEGF
VEGF
VEGF/EGFR
Hypermethylated TSG promoters
Hypermethylated TSG promoters
Topoisomerase I
Histone deacetylase
20S proteasome

Endostatin
Bevacizumab
VEGF Trap
Sunitinib
Pazopanib
ZD6474
5-Aza-CR
5-Aza-CdR
Irinotecan
Vorinostat
Bortezomib

Delivery of functional TP53 into cells (Pagliaro et al 2003b)
Delivery of functional TP53 into cells (Fodor et al 2005)
Delivery of functional TP53 into cells (Khuri et al 2000)
Restores mutant p53; stabilizes wild-type p53 (Ho and Li 2005;
Tanner and Barberis 2004)
Restores transcriptional activity of mutant p53 (Bykov et al 2005)
Replaces Rb function (Zhang et al 2003)
Nonspecific cyclin-dependent kinase inhibitor (Senderowicz 2003b)
Nonspecific cyclin-dependent kinase inhibitor (Senderowicz 2003b)
Inhibition of tyrosine kinase activity (Ciardiello et al 2000)
Inhibition of tyrosine kinase activity (Lindsey 2006; Meyerhardt et al 2006)
Prevents signal transduction (Inoue et al 2000)
Inhibits HER2 and activates anti-tumor immune response (Hussain et al 2007;
Sawyers 2002; Small et al 2003)
Multikinase inhibitor (Carter et al 2007; Kupsch et al 2005; Panka et al 2006;
Siu et al 2006)
Inhibition of cell growth and migration (Kikuchi et al 2004)
Binds and inactivates VEGF (Jain et al 2006)
Binds and inactivates VEGF (Kim et al 2002)
Inhibition of tyrosine kinase activity (Silay and Miroglu 2007)
Inhibition of tyrosine kinase activity (ClinicalTrials.gov)
Inhibition of tyrosine kinase activity (Ciardiello et al 2003)
DNA incorporated (Mitra et al 2006)
DNA incorporated (Yoo and Jones 2006)
Topoisomerase I inhibition (ClinicalTrials.gov)
Histone deacetylase inhibitor (ClinicalTrials.gov)
dipeptidyl boronic acid inhibitor (Calabro and Sternberg 2006)
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Targeting cell cycle regulators
The knowledge that genetic alterations of the TP53 gene
occur in up to 70% of muscle-invasive bladder cancers
(Knowles 2001) make TP53 gene an extremely attractive
target for rationally designed therapies. Small molecules that
can directly restore TP53 function are CP-31398 (Foster et al
1999), which should restore the conformational structure and
DNA-binding ability of mutant p53, and PRIMA-1 (P53
Reactivation and Induction of Massive Apoptosis-1), which
has been shown to suppress the growth of cells expressing
mutant p53 (Bykov et al 2002) and to synergize with cisplatinum to induce tumor cell apoptosis (Bykov et al 2005).
However, the most suitable approach to target p53 pathway, seems to be the direct delivery of wild-type TP53 gene
by viral vector in intra-vesical instillation. The ﬁrst clinical
trial involving intra-vesical delivery of a gene therapy vector
(vaccinia virus) has been published by our group (Gomella
et al 2001). The vector used has been subsequently recombined with TP53 (rVV-TK-53) in orthotopic murine animals
(Fodor et al 2005). Similar gene therapy trials, in which
adenovirus containing TP53 gene (AdCMV-TP53) was used,
have demonstrated tumor inhibition in bladder cancer cell
lines and xenograft models (Pagliaro, Keyhani, Liu et al
2003). Two similar adenoviral vectors containing the TP53
gene have been instilled into the bladder, both as single and
multiple instillations, and have led to expression of functional
p53 that can be detected in the bladder epithelium (Kuball
et al 2002; Pagliaro, Keyhani, Liu et al 2003). In addiction,
these trials involving intravesical instillation of the vector
have revealed a high level of tolerance, increased transduction efﬁcacy and expression when used in combination with
transduction-enhancing agents (Kuball et al 2002; Pagliaro,
Keyhani, Liu et al 2003), and a synergistic effect in combination of cisplatin leading to increased apoptosis (Pagliaro,
Keyhani, Williams et al 2003). Pagliaro, Keyhani, Williams
et al (2003), observed evidence of tumor response in one of
13 advanced superﬁcial bladder cancers treated.
Another gene therapy viral vector, which might be used
in the delivery of a normal TP53 gene in bladder cancer
cells, involves the selectively replicating adenovirus dl1520
(ONYX-015) (Heise et al 1997). Deletion of the E1B 55
kDa protein gene from the viral genome results in selective
replication of cells that lack a functional p53 pathway. In
normal cells with functional p53, the virus cannot replicate
and is therefore harmless (Heise et al 1997; Ries and Korn
2002). In a number of Phase I and Phase II clinical trials,
the use of this viral vector has demonstrated a safety record
and has been shown to be effective in combination with
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cisplatin, as combined-modality therapy (Khuri et al 2000).
In a single study, treatment caused tumors to shrink in 25
of the 30 cases evaluated (Khuri et al 2000). Objective
responses (decrease of 50% or more) of injected tumors were
documented in 63% of patients who could be evaluated (19
of 30). There were 8 (27%) complete and 11 (36%) partial
responses. ONYX-015 therefore represents an attractive
agent for the treatment of the majority of high-risk TP53
mutant bladder cancers. Similarly, conditionally replicating
E1a-deleted adenoviruses (Hernandez-Alcoceba et al 2000)
may selectively target approximately 37% of muscleinvasive bladder cancers which have shown mutations in
the RB1 tumor suppressor gene. In normal bladder cells with
functional Rb1, the absence of viral E1a gene function will
prevent replication of the viral genome. However, in bladder tumors with mutant Rb1, there should be no effective
barrier to viral replication and as with ONYX-015 in p53defective cells, the virus would be expected to be selectively
apoptotic. Another vector carrying RB1 is Ad-RB94, which
is a replication-deﬁcient adenoviral construct with Rb94, a
protein which lacks 112 amino acid residues of the wild-type
Rb1 protein (Rb110) resulting in a more potent tumor and
growth suppressor than the normal protein (Xu et al 1994).
This vector has been observed to be very selective to both
bladder cancer RB1-negative and RB1-positive cells, inducing growth suppression and caspase-dependent apoptosis
(Zhang et al 2003).
Recent data proposed hyper-phosphorylation of RB1 as
mechanism for Rb1 tumor suppressor pathway inactivation in bladder cancer (Chan et al 2002). Thus, a treatment
leading to hypo-phosphorylation of the wild-type RB1
promoter using CDKIs may improve prognosis. Recently,
non-specific CDKIs like flavopiridol (L86-8275) and
UCN-01 (7-hydroxystaurosporine) have entered clinical
trials (Senderowicz 2003b). Moreover, ﬂavopiridol also
decreases cyclin D1 levels, which are elevated in many UC
cases (Senderowicz 2003a).

Targeting growth factor receptors
Two of the principal targets in the signal transduction cascade
in metastatic and invasive tumors are EGFR and erbB-2
proteins (Bellmunt, de Wit et al 2003; Bellmunt, Hussain
et al 2003). A series of studies targeting both the EGFR and
the erbB-2, which are overexpressed or ampliﬁed in bladder
cancer (Bue et al 1998; Gardmark et al 2005; Jimenez et al
2001; Scholl et al 2001; Wester et al 2002), are under way
and will help to deﬁne the role of these new targeted therapies
in the treatment of advanced UCs.
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Several strategies have been designed to target these
receptor tyrosine kinases (Mendelsohn 2000). The two
most studied approaches to targeting EGFR are monoclonal antibodies against the extracellular domain of the
receptor (Cetuximab/IMC-C225 [Erbitux]) and inhibitors of the receptor tyrosine kinase domain (Geﬁtinib/
ZD1389 [Iressa], Erlotinib/OSI-774 [Tarceva]) (de Bono
and Rowinsky 2002; Mendelsohn 2002). Trastuzumab
(Herceptin), a monoclonal antibody against erbB-2, has
prompted the initiation of a phase I/II clinical trial to
determine the toxicity of combined chemo-radiotherapy
(paclitaxel, carboplatin and gemcitabine) with or without
this agent in patients with prior cystectomies for muscle
invasive bladder cancer (ClinicalTrials.gov; Hussain et al
2003; Calabro and Sternberg 2006; Hussain et al 2007).
A recently introduced agent, sorafenib (BAY 43-9006
[Nexavar]), is a multikinase inhibitor targeting various
molecules, including EGFR and erbB-2, and is currently
in phase II clinical trials for advanced and metastatic UC
(ClinicalTrials.gov).
Based on the success seen with anti-erb-2 monoclonal
antibodies and the promising results with EGFR targeted
agents in other tumor types, there is a great interest in assessing these agents in patients with bladder cancer. Inhibition
of EGFR and erbB-2 pathways, either by physical receptor
blockade or with small molecule inhibitors of the receptor’s
tyrosine kinase activity, leads to demonstrable anti-tumor
effects in animal models (Nicholson et al 2001; Mendelsohn
2002; Hidalgo 2003). More importantly, multiple reports
conﬁrm that EGFR directed therapy in combination with
cytotoxics produces a much-enhanced biologic effect
(Mendelsohn 2002). Blocking signaling through EGFR on
tumor cell surfaces can promote apoptosis, inhibit angiogenesis and metastases, and consequently cause tumor regression
(Izawa et al 2001).
Geﬁtinib, as erlotinib, inhibits the activity of tyrosine
kinase in the intracellular component of the EGFR, thus
preventing receptor autophosphorylation and subsequent
activation (Slichenmyer and Fry 2001). The combination
with platinum-derived agents (cisplatin, oxaliplatin, carboplatin), taxanes (paclitaxel, docetaxel) and topoisomerase
inhibitors, shows enhanced growth inhibition (Ciardiello
et al 2000). Its anti-proliferative effect in bladder cancers
has been demonstrated in vitro and in vivo, and now it is
in phase II clinical trials for advanced or metastatic UC
(ClinicalTrials.gov; Dominguez-Escrig et al 2004; Nutt
et al 2004). Erlotinib, in combination with green tea extract
(Polyphenon E) is under study in a phase II clinical trial for
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preventing cancer recurrence in former smokers with resected
UC (ClinicalTrials.gov).
Cetuximab binds to the EGFR with high afﬁnity, blocks
ligand-induced tyrosine kinase activity and stimulates receptor internalization. In vitro, proliferation of 253J B-V cells
was inhibited more by the combination of cetuzimab and
paclitaxel than with either cetuzimab or paclitaxel (Inoue
et al 2000). The combination enhanced apoptosis in tumor
and endothelial cells compared with either agent alone, most
likely mediated by inhibition of angiogenesis and induction of apoptosis (Perrotte et al 1999). The combination of
cetuximab and paclitaxel has been evaluated in mice with
metastatic human bladder UC with encouraging results
(Inoue et al 2000).

New therapeutic targets
One of the mechanisms used in cell transformation is the
escape from the normal control mechanisms of the apoptotic
process. In the attempt to predispose cancer cells to apoptosis,
anti-sense oligonucleotide gene therapy directed to BCL-2
mRNA has already been demonstrated to reverse cisplatin
resistance in bladder tumor cell lines in vitro, (Hussain et al
2003) and it will be interesting to see whether these results
can be reproduced in pre-clinical models and in clinical
trials.
Recently, the importance of VEGF and bFGF in advanced
and metastatic UC has grown and a number of agents have
been designed against them, many of which have already
entered clinical trials. The most popular is endostatin, which
decreases VEGF expression and tumor growth by inducing
apoptosis (Du and Hou 2003). Moreover, the lentiviral gene
transfer of endostatin by intravesical instillation decreases
orthotopic human bladder tumor growth (Kikuchi et al
2004). Bevacizumab (Avastin), a monoclonal antibody
against VEGF, already used for other type of cancers (Jain
et al 2006), is in phase II clinical trials in combination with
cisplatin and gemcitabine for metastatic UC (ClinicalTrials.
gov). VEGF Trap consists in a fully humanized, soluble
decoy VEGF receptor generated by fusing the extracellular
domains of VEGFR-1 and VEGFR-2 to the Fc portion of
human IgG1. The mechanism of action is very similar to
bevacizumab, binding and inactivating VEGF. In preclinical models it inhibits tumor growth and angiogenesis (Kim
et al 2002). In addition, it is in use in clinical trials against
metastatic UCs (ClinicalTrials.gov).
Bortezomib (PS-341) is a dipeptidyl boronic acid inhibitor of the 20S proteasome, which also inhibits secretion
of the pro-angiogenic factors matrix metalloproteinase-9,
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interleukin-8 (IL-8), and vascular endothelial growth
factor (VEGF) (Zavrski et al 2005). The effects of bortezomib on the growth of human 253JB-V bladder cancer
cells showed inhibition of cell growth in a concentrationdependent fashion and higher growth inhibitory effects of
gemcitabine in vitro (Calabro and Sternberg 2006). These
effects were associated with accumulation of p53 and p21
and suppression of cyclin-dependent kinase 2 activity. In
vivo studies with 253JB-V tumors growing in nude mice
demonstrated that bortezomib did not inhibit tumor growth
when it was delivered as a single agent. However, the
combination therapy with bortezomib plus gemcitabine
produced synergistic tumor growth inhibition associated
with strong suppression of tumor cell proliferation (Calabro
and Sternberg 2006).
The role of hyper-methylation of tumor suppressor gene
promoters in UC has recently been stressed, highlighting
the importance of using demethylating agents to reverse the
hypermethylation in advanced and metastatic UCs (Cote
et al 2005). The most used agents are nucleoside analogs
such as 5-azacytidine (5-Aza-CR), 5-aza-2'-deoxycitidine
(5-Aza-CdR, decitabine), and zebularine. These therapeutics
have a modiﬁed cytosine ring attached to either a ribose or
deoxyribose moiety, which inhibits the DNA methylation
(Yoo and Jones 2006) and they are now under study in the
treatment of UC.
Apart from the herein mentioned therapeutic agents, other
inhibitor classes such as anti-topoisomerase I (Irinotecan)
and histone deacetylase inhibitors (vorinostat) are used at the
moment in clinical trials for the treatment of advanced and
metastatic UC (ClinicalTrials.gov), but further investigations
are needed to clarify their role in bladder cancer treatment.

Conclusion
Although bladder cancer is one of the leading tumors in
western world, very little is still known about the molecular
mechanisms that determine tumor formation in the bladder urothelium and the process of its metastatization. A
better understanding of the molecular biology of bladder
cancer will undoubtedly inﬂuence the selection of new
therapeutic modalities. The value of integrating new biologically targeted agents into combined modality treatment
for patients with metastatic bladder cancer has still to be
proven. However, efﬁciently designed and rationalized
trials, targeting therapeutic approaches to the molecular
and histological characteristics of urothelial cancers, hold
promise to improve the current results of metastatic bladder
cancer treatment.
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